Cell-based drugs developer Promethera Biosciences has closed a Series D financing round to support its expansion in Asian markets, along with the development of liver disease programmes.
The funding round previously fetched €39.7m, followed by additional €7.5m from Sony Innovation Fund by IGV and Pegasus Tech Ventures.
Go deeper with GlobalData
Furthermore, Medipal Holdings, Six Snow, a Japanese private investor and a Belgian private investor, joined the extension.
The company’s office in Tokyo, Japan, will act as a base for its expansion in Asia.
Moreover, the company will use the proceeds to launch clinical trials of programmes to treat non-alcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF) in ex-European markets next year.
A trial in NASH commenced in the first half of this year. The company is also conducting a Phase IIa trial in patients with ACLF or those with acute decompensation (AD) at high risk of developing ACLF.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPromethera Group president and CEO John Tchelingerian said: “The additional investment by Sony Innovation Fund by IGV and Pegasus Tech Ventures continues to acknowledge the potential of our HepaStem technology.
“With the additional funds provided by the Series D expansion, Promethera plans to further solidify its position as the leading drug development organisation in cell-based therapies and regenerative medicines targeting severe liver disorders.”
The company’s HepaStem is made up of liver-derived stem cells extracted from donated healthy human organs and then expanded in culture conditions.
As well as cell-based drugs, Promethera is developing a portfolio of complementary biologics treatments, including the anti-TNF-R1 antibody Atrosimab, obtained with the acquisition of Swiss biopharmaceutical firm Baliopharm last year.
